Literature DB >> 2299613

Prolongation of premature gestation in women with hemolysis, elevated liver enzymes and low platelets. A report of five cases.

K D Heyborne1, M S Burke, R P Porreco.   

Abstract

Severe pregnancy-induced hypertension complicated by hemolysis, elevated liver enzymes and low platelets (HELLP) is considered an indication for immediate delivery, often resulting in premature or even previable infants. In five cases, temporary reversal of the HELLP syndrome was achieved using low-dose aspirin and corticosteroids. Pregnancy was prolonged an average of 4 weeks; three pregnancies were prolonged, beginning at less than or equal to 25 weeks, for an average of 5.5 weeks. Two of seven infants died, one from pulmonary hypoplasia due to oligohydramnios and the other from complications of prematurity. No long-term maternal morbidity was encountered, though one patient had peripartum disseminated intravascular coagulation and a seizure. A review of the literature supports the usefulness of low-dose aspirin in this setting; the impact of corticosteroids as part of the reversal strategy has not been discussed previously.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299613

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

Review 1.  Liver diseases in pregnancy: diseases unique to pregnancy.

Authors:  Khulood T Ahmed; Ashraf A Almashhrawi; Rubayat N Rahman; Ghassan M Hammoud; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 2.  [HELLP syndrome: report of 61 cases and literature review].

Authors:  Nisrine Mamouni; Hakima Bougern; Ali Derkaoui; Karima Bendahou; Samira Fakir; Chehrazad Bouchikhi; Hikmat Chaara; Abdelaziz Banani; Moulay Abdelilah Melhouf
Journal:  Pan Afr Med J       Date:  2012-02-20

3.  COHELLP: collaborative randomized controlled trial on corticosteroids in HELLP syndrome.

Authors:  Leila Katz; Melania Amorim; João P Souza; Samira M Haddad; José G Cecatti
Journal:  Reprod Health       Date:  2013-05-22       Impact factor: 3.223

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.